These two studies showed a trend of improvement in alanine aminotransferase (ALT) but there was no significant improvement when all four studies with information on ALT were included in the meta-analysis ( Supplementary Fig. 2 ).
← all excerpts
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis.
1
—
—